For the acute treatment of migraine and the preventive treatment of episodic migraine in adults.
We're here to help! To request samples or other materials, or for other inquiries about Nurtec ODT, please fill out the form below to connect with a sales representative. You can also call us Monday–Friday 8:30AM–8PM ET at 1‑833‑4NURTEC (1‑833‑468‑7832) to connect with Nurtec® OneSource for support in getting Nurtec ODT for you and your patients.
< Previous Page
Resources
Contraindications: Hypersensitivity to Nurtec ODT or any of its components.
Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.
Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.
Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.
Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.
Nurtec ODT is indicated in adults for the:
Please click here for full Prescribing Information.
US-RIMODT-2000690 10/13/2020
Individual results may vary.
From 2-48 hours
48h
68% of patients taking Nurtec ODT with normal functioning at 2 hours had a sustained response through 48 hours
68% (n=174/255) of patients taking Nurtec ODT vs 60% (n=105/176) of patients taking placebo
26% of patients taking Nurtec ODT 75 mg (n=174/669) experienced return to normal function from 2‑48 hours vs 15% of patients taking placebo (n=105/682); P<.0001
From 2-48 hours
48h
71% of patients taking Nurtec ODT who achieved pain relief at 2 hours experienced sustained pain relief through 48 hours
71% (n=282/397) of patients taking Nurtec ODT vs 58% (n=172/295) of patients taking placebo
42% of patients taking Nurtec ODT 75 mg (n=282/669) experienced pain relief from 2‑48 h vs 25% of patients taking placebo (n=172/682); P<.0001
Freedom from pain
Pain relief
NURTEC ODT:
75 mg as needed -
max 1 dose q 24 hours
DISP:
1 pack per 30 days or
8 tabs per 30 days
NURTEC ODT:
75 mg QOD for
preventive
treatment
of episodic migraine
DISP:
2 packs per 30 days or
16 tabs per 30 days
